sector medic suppli devic
 impella strong momentum continu
messag report strong result revenu
yoy come consensu ep top street
expect growth slow modestli back half year due tougher comp
convict long-term growth outlook remain unchang driven
under-penetrated exist end market robust pipelin potenti new indic
new indic front continu see upcom dtu data aha
like posit catalyst stock would add posit ahead meet
follow result updat estim
beyond expect full year adjust ep yoy total revenu
cc compar prior forecast ep
sale chosen keep full year revenu estim rel unchang despit
solid beat believ prior forecast underst impact difficult
comparison back half year refer grew sale clip
vs revenu estim remain high end
manag revis guidanc rang incom statement
project full year oper margin yoy within upper half
compani forecast
continu believ impella growth stori still earli inning
model call grow revenu compound-annual-growth-rate sale
reach end period note includ potenti
contribut new stemi indic expect visibl
regulatori pathway indic might look like follow present dtu
trial result sunday novemb host investor call monday
novemb et review data wrote earlier week see
analysi pre-clin work done date evalu possibl impact mechan
unload infarct size suggest us studi high likelihood success
would view first step toward unlock new market opportun
impella broader stemi popul dcf-deriv price target
also includ valu stemi unchang signific upsid potenti
price target current level reiter buy rate
page analyst certif import disclosur
leader mechan circulatori support dedic enabl safer
treatment high-risk patient cardiovascular diseas recov injur heart
muscl estim patient receiv one compani famili impella
heart pump year yet believ scratch surfac impella
long-term potenti estim market opportun includ
stemi see long runway growth level compani match
impella smallest heart pump world design provid temporari
hemodynam support patient undergo high-risk procedur whose cardiac
function compromis sinc impella first receiv approv
impella famili pump use support ten thousand peopl
abiom revenu grow compound-annual-growth-rate period go forward expect
ramp penetr protect pci cardiogen shock indic drive
continu strong growth compani still earli inning
capit intern opportun impella well recent guidelin
chang germani entri japanes market provid ampl momentum
go forward model call grow total revenu compound-annual-growth-rate
combin strong margin clean balanc sheet limit competit
view one best growth stori med-tech
share trade ntm revenu estim signific premium
multipl high-growth peer smid-cap med-tech group believ
abiom uniqu combin top line growth potenti compound-annual-growth-rate
profit gm om make compani difficult valu base
tradit metric result employ discount cash flow methodolog deriv
fair valu estim assum wacc termin growth rate
calcul forward npv per share target equat multipl
forward ntm sale estim signific potenti upsid target
current level assign buy rate
downsid risk rate includ potenti impella adopt fall short
street forecast pipelin setback clinic failur weaken abiom long-term
outlook faster-than-expect progress potenti impella competitor
premium valuat leav littl margin error view
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
servic
revenu geographi
 unit
 unit indic
compani report guggenheim secur llc estim
page analyst certif import disclosur
